Moreover, 5 out of 7 genes in the leading edge of our gene set enrichment analysis were previously identified as key candidates (S100P, GAB2, NFKBIA, TNFAIP3, and PPP1R15A) for molecular signatures of disease activity in myasthenia gravis, highlighting the validity of our independently prioritized genes from GWAS results. This evidence concerns the gene PPP1R15A and myasthenia gravis.